IDEXX Laboratories Launches the IDEXX VetLab® UA™ Analyzer and Strips
Introducing the first urine strip analyzer validated specifically for canine, feline and equine patients

Westbrook, Maine, October 25, 2006—IDEXX Laboratories, Inc. (NASDAQ: IDXX), has launched the IDEXX VetLab® UA™ Analyzer and Strips to provide veterinary professionals with an easier, more efficient and consistent method of conducting urinalysis. This analyzer is the newest member of the IDEXX VetLab® Suite, the world's most complete in-house veterinary laboratory. It will provide a more comprehensive diagnostic solution to the veterinarian and fill an important gap in integrated reporting, trending and patient results management through its integration with the IDEXX VetLab® Station. The IDEXX UA™ Strips, specifically validated for the veterinary market, can be used manually or with the new IDEXX VetLab UA Analyzer.

According to Dr. Michelle Frye, Medical Affairs Manager at IDEXX Laboratories, “The IDEXX VetLab UA Analyzer and IDEXX UA Strips allow practices to confidently and accurately perform urinalyses in-house. It has been well established that the urinalysis is a critical part of the minimum database of diagnostic testing for sick animals. This system marks the first in-house urinalysis test specifically validated for veterinary medicine. The new IDEXX VetLab UA Analyzer is simple to operate, improves clinic workflow and produces consistent results on a professional printout. When combined with a urine sediment exam, this test provides unparalleled accuracy and precision for in-house urinalysis testing.” The IDEXX VetLab UA Analyzer reads IDEXX UA Strips automatically with photo reflectance, compensating for the intrinsic urine color with a compensation pad on the strips. This automatic read ensures consistent, reliable results. The analyzer offers one-button operation with a simple user interface navigated via three menu buttons, and the combined analysis time for each test strip is approximately 70 seconds.

The analyzer generates a detailed print report of the urinalysis test results and automatically captures the data electronically, linking it to the IDEXX VetLab Station or LaserCyte® Hematology Analyzer. Through this connectivity, the urinalysis results are included on an integrated patient report that provides hematology, chemistry, electrolytes and endocrinology results from the complete IDEXX VetLab Suite.

This report can be a critical educational tool when assessing a patient’s condition and discussing diagnoses and treatment plans with clients.

For more information or to place an order, practitioners can contact their authorized IDEXX distributor representative, call IDEXX at 1-800-355-2896 or visit www.idexx.com/ua.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and therapeutics. Our products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 3,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to develop, license or obtain rights to new technologies; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 (1.5 MB) and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2006, (506 KB) in the section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”